You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the Australian regulatory environment.
For Australian specific enquiries, please click here.
You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for, and exercises no control over the organisation, views, or information contained on the server or site which you will be accessing. The information contained might not comply with the Australian regulatory environment.
As an industry leader in the development of innovative medicines and biosimilars, Amgen advocates for policies based on rigorous science that will improve and protect the health of patients with serious illnesses, support advances in clinical development and enhance access to medicines.
Access to medicines - At Amgen, we believe that breakthrough medicines are the best hope for patients in the fight against serious diseases. To realise the full value of our medicines and for the people who need them most, Amgen engages with stakeholders across the health system.
Amgen works constructively with payers, health technology assessment (HTA) agencies and policymakers, in Australia and around the world, to find pragmatic solutions to shared challenges, ensure patients get access to the medicines they need when they need them, and drive improvements in health outcomes.
Our team contributes to technical debates on the timely reimbursement of medicines and is engaging in discussions globally on valuing medicines and financing their reimbursement across different healthcare systems.
In Australia, we are keenly interested in ensuring that the recommended reforms to Australia’s HTA system are implemented in a timely fashion and continue to advocate for the systematic collection, collation and publication by the Australian Government of data on the performance of the PBS listing process as an essential aspect of reform.
In the interim, Amgen’s Australian Patient Access Gap Tracker provides contemporary analysis of how long patients are waiting for equitable access to important health technologies.
Cardiovascular disease (CVD) – Amgen strives to drive urgency to identify, treat and manage CVD patients, including those with elevated LDL-C who may be at high risk of a cardiovascular event.
Amgen Australia recently commissioned the report, Confronting Cholesterol: Bringing it All Together to Solve Australia’s ASCVD Crisis, to foster discussion around the key barriers and challenges to optimal cholesterol management, and to provide practical recommendations.These efforts add to Amgen’s commitment to tackle cardiometabolic disease globally, including the bold vision in our JAPAC region to help reduce the number of heart attacks and strokes by 30% by 2030.